Rice Hall James & Associates LLC Has $6.60 Million Holdings in Urogen Pharma $URGN

Rice Hall James & Associates LLC lifted its stake in shares of Urogen Pharma (NASDAQ:URGN) by 8.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 281,876 shares of the company’s stock after buying an additional 22,733 shares during the period. Rice Hall James & Associates LLC owned about 0.60% of Urogen Pharma worth $6,602,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new position in shares of Urogen Pharma during the fourth quarter worth $535,000. MML Investors Services LLC acquired a new stake in shares of Urogen Pharma during the fourth quarter valued at about $571,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Urogen Pharma during the fourth quarter valued at about $26,350,000. Barclays PLC boosted its stake in shares of Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock valued at $1,352,000 after purchasing an additional 2,125 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Urogen Pharma by 55.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 55,686 shares of the company’s stock valued at $1,293,000 after purchasing an additional 19,749 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on URGN. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research note on Monday, May 11th. They set a “buy” rating and a $43.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a research note on Wednesday, June 3rd. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. Finally, D. Boral Capital reissued a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.50.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 5,222 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $27.30, for a total value of $142,560.60. Following the completion of the sale, the insider directly owned 139,763 shares in the company, valued at $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.80% of the stock is owned by insiders.

Urogen Pharma Stock Up 3.8%

NASDAQ URGN opened at $30.86 on Tuesday. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -11.22 and a beta of 1.59. Urogen Pharma has a twelve month low of $12.61 and a twelve month high of $32.37. The stock has a fifty day simple moving average of $25.96 and a 200 day simple moving average of $22.86.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. Research analysts expect that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.